Biparatopic receptor-based bispecific ADCs (Antibody-Drug Conjugates) are an advanced class of therapeutics designed to target and destroy cancer cells with high specificity and potency. They integrate several cutting-edge biological technologies, including bispecific antibodies, biparatopic targeting, and the cytotoxic effects of ADCs.
Søg
Populære opslag